Northern Trust’s Sonnet BioTherapeutics SONN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-17,860
| Closed | -$81.8K | – | 4539 |
|
|
2025
Q3 | $81.8K | Buy |
+17,860
| New | +$79.2K | ﹤0.01% | 4179 |
|
|
2023
Q3 | – | Sell |
-101
| Closed | -$8.75K | – | 4521 |
|
|
2023
Q2 | $8.75K | Hold |
101
| – | – | ﹤0.01% | 4485 |
|
|
2023
Q1 | $6.43K | Buy |
+101
| New | +$16.3K | ﹤0.01% | 4557 |
|
|
2022
Q3 | – | Sell |
-18
| Closed | -$12K | – | 4757 |
|
|
2022
Q2 | $12K | Hold |
18
| – | – | ﹤0.01% | 4681 |
|
|
2022
Q1 | $16K | Hold |
18
| – | – | ﹤0.01% | 4682 |
|
|
2021
Q4 | $18K | Buy |
+18
| New | +$25.8K | ﹤0.01% | 4712 |
|
|
2020
Q2 | – | Hold |
0
| – | -$4K | – | 4300 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 4196 |
|
|
2017
Q2 | – | Hold |
0
| – | -$6K | – | 4299 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4211 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 4149 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 4134 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 4170 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4155 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 4179 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 4185 |
|
Other funds holding SONN
Northern Trust's SONN Position: Q4 2025 in Review
Northern Trust sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 17,860 shares — an estimated $81.8K sold.
Northern Trust first reported a position in SONN in Q4 2021 and held it in 6 quarters. The position peaked at $81.8K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.
- Northern Trust reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
- Northern Trust sold 17,860 Sonnet BioTherapeutics shares in Q4 2025, an estimated $81.8K.
- Northern Trust first reported a position in Sonnet BioTherapeutics in Q4 2021 and held it in 6 quarters.
- Northern Trust's Sonnet BioTherapeutics position peaked at $81.8K in Q3 2025.
- 1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.
Based on Northern Trust's 13F filing for Q4 2025, filed 17 Feb 2026.